Misplaced Pages

:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Amikacin: Difference between pages - Misplaced Pages

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Difference between pages)
Page 1
Page 2
Content deleted Content addedVisualWikitext
Revision as of 09:49, 6 December 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{drugbox}} taken from revid 464320858 of page Amikacin for the Chem/Drugbox validation project (updated: 'DrugBank').  Latest revision as of 07:26, 30 November 2024 edit Whywhenwhohow (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers49,136 edits EML 
Line 1: Line 1:
{{Short description|Antibiotic medication}}
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}}
{{Use dmy dates|date=March 2024}}
{{Drugbox
{{cs1 config |name-list-style=vanc |display-authors=6}}
| Verifiedfields = changed
{{Infobox drug
| verifiedrevid = 456687971
| Watchedfields = changed
| IUPAC_name = (2''S'')-4-amino-N-oxy-4-oxy-3-hydroxy-cyclohexyl]-2-hydroxy-<br>butanamide
| verifiedrevid = 464364466
| image = Amikacin.svg | image = Amikacin.svg
| width =
| alt =
| image2 = Amikacin 3D ball-and-stick 4P20.png
| width2 =
| alt2 =
| caption =


<!--Clinical data--> <!-- Clinical data -->
| pronounce =
| tradename = Amikin
| tradename = Amikin, Amiglyde-V, Arikayce, others
| Drugs.com = {{drugs.com|monograph|amikacin-sulfate}} | Drugs.com = {{drugs.com|monograph|amikacin-sulfate}}
| MedlinePlus = a682661 | MedlinePlus = a682661
| DailyMedID = Amikacin
| pregnancy_AU = D
| pregnancy_US = C | pregnancy_AU = D
| pregnancy_AU_comment = <ref name="Drugs.com pregnancy">{{cite web | title=Amikacin Use During Pregnancy | website=Drugs.com | date=2 December 2019 | url=https://www.drugs.com/pregnancy/amikacin.html | access-date=13 March 2020}}</ref>
| pregnancy_category=
| routes_of_administration = ], ], ]
| class = ]
| ATCvet =
| ATC_prefix = D06
| ATC_suffix = AX12
| ATC_supplemental = {{ATC|J01|GB06}}, {{ATC|S01|AA21}}, {{ATC|J01|RA06}}, {{ATCvet|D06|AX12}}, {{ATCvet|J01|GB06}}, {{ATCvet|S01|AA21}}, {{ATCvet|J01|RA06}}

<!-- Legal status -->
| legal_AU = S4
| legal_AU_comment = <ref>{{cite web | title=Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017 | website=Therapeutic Goods Administration (TGA) | date=21 June 2022 | url=https://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017 | access-date=30 March 2024}}</ref>
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->
| legal_BR_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment =
| legal_DE = <!-- Anlage I, II, III or Unscheduled-->
| legal_DE_comment =
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment =
| legal_UK = POM | legal_UK = POM
| legal_UK_comment = <ref>{{cite web | title=Amikacin 250 mg/ml Injection - Summary of Product Characteristics (SmPC) | website=(emc) | date=16 September 2015 | url=https://www.medicines.org.uk/emc/medicine/619 | access-date=13 March 2020}}</ref>
| legal_US = Rx-only | legal_US = Rx-only
| legal_US_comment = <ref name="Arikayce FDA label" />
| routes_of_administration = ], ]
| legal_EU = Rx-only
| legal_EU_comment = <ref name="Arikayce liposomal EPAR">{{cite web | title=Arikayce liposomal EPAR | website=European Medicines Agency | date=21 July 2020 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/arikayce-liposomal | access-date=4 March 2023}}</ref><ref>{{cite web | title=Arikayce liposomal Product information | website=Union Register of medicinal products | url=https://ec.europa.eu/health/documents/community-register/html/h1469.htm | access-date=3 March 2023}}</ref>
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_UN_comment =
| legal_status = <!--For countries not listed above-->


<!--Pharmacokinetic data--> <!-- Pharmacokinetic data -->
| bioavailability = | bioavailability = >90%<ref name="plumb"/>
| protein_bound = 0-11% | protein_bound = 0–11%
| metabolism = | metabolism = Mostly unmetabolized
| metabolites =
| elimination_half-life = 2-3 hours
| onset =
| excretion = ]
| elimination_half-life = 2–3 hours
| duration_of_action =
| excretion = ]


<!--Identifiers--> <!-- Identifiers -->
| index2_label = as salt
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}} | CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 37517-28-5 | CAS_number = 37517-28-5
| CAS_supplemental =
| ATC_prefix = D06
| ATC_suffix = AX12
| ATC_supplemental = {{ATC|J01|GB06}}, {{ATC|S01|AA21}}
| PubChem = 37768 | PubChem = 37768
| IUPHAR_ligand =
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00479 | DrugBank = DB00479
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
Line 39: Line 75:
| KEGG_Ref = {{keggcite|correct|kegg}} | KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02543 | KEGG = D02543
| KEGG2_Ref = {{keggcite|correct|kegg}}
| KEGG2 = D00865
| ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 2637 | ChEBI = 2637
| ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 177 | ChEMBL = 177
| NIAID_ChemDB =
| PDB_ligand =
| synonyms =


<!--Chemical data--> <!-- Chemical and physical data -->
| IUPAC_name = (2''S'')-4-Amino-''N''-oxy-4-oxy-3-hydroxy-cyclohexyl]-2-hydroxybutanamide
| C=22 | H=43 | N=5 | O=13
| C=22 | H=43 | N=5 | O=13
| molecular_weight = 585.603 g/mol
| smiles = O=C(N3(O1O((O)(N)1O)CO)(O)(O2O(CN)(O)(O)2O)(N)C3)(O)CCN | SMILES = O=C(N3(O1O((O)(N)1O)CO)(O)(O2O(CN)(O)(O)2O)(N)C3)(O)CCN
| InChI = 1/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1
| InChIKey = LKCWBDHBTVXHDL-RMDFUYIEBW
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1 | StdInChI = 1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1
| StdInChI_comment =
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = LKCWBDHBTVXHDL-RMDFUYIESA-N | StdInChIKey = LKCWBDHBTVXHDL-RMDFUYIESA-N
| density =
| density_notes =
| melting_point =
| melting_high =
| melting_notes =
| boiling_point =
| boiling_notes =
| solubility =
| sol_units =
| specific_rotation =
}} }}

<!-- Definition and medical uses -->
'''Amikacin''' is an ] medication used for a number of ].<ref name=AHFS2016>{{cite web|url=https://www.drugs.com/monograph/amikacin-sulfate.html|title=Amikacin Sulfate|publisher=The American Society of Health-System Pharmacists|access-date=8 December 2016|url-status=live|archive-url=https://web.archive.org/web/20161220231044/https://www.drugs.com/monograph/amikacin-sulfate.html|archive-date=20 December 2016}}</ref> This includes ], ]s, ], ], ], and ]s.<ref name=AHFS2016/> It is also used for the treatment of ].<ref name=WHO2008>{{cite book | title = WHO Model Formulary 2008 | year = 2009 | isbn = 9789241547659 | vauthors = ((World Health Organization)) | veditors = Stuart MC, Kouimtzi M, Hill SR | hdl = 10665/44053 | author-link = World Health Organization | publisher = World Health Organization | hdl-access=free |page=137}}</ref> It is used by injection ] or ].<ref name=AHFS2016/>

<!-- Side effects and mechanism -->
Amikacin, like other ], can cause ], balance problems, and ].<ref name=AHFS2016/> Other side effects include ], resulting in the inability to breathe.<ref name=AHFS2016/> If used during ] it may cause permanent deafness in the baby.<ref name=AHFS2016/><ref name="Drugs.com pregnancy" /> Amikacin works by blocking the function of the bacteria's ], making it unable to produce ]s.<ref name=AHFS2016/>

<!-- History, society and culture -->
Amikacin was patented in 1971, and came into commercial use in 1976.<ref>{{cite book| vauthors = Fischer J, Ganellin CR |title=Analogue-based Drug Discovery|date=2006|publisher=John Wiley & Sons|isbn=9783527607495|page=507|url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA507|url-status=live|archive-url=https://web.archive.org/web/20161220092307/https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA507|archive-date=20 December 2016}}</ref><ref>{{cite book|title=Oxford Handbook of Infectious Diseases and Microbiology|date=2009|publisher=OUP Oxford|isbn=9780191039621|page=56|url=https://books.google.com/books?id=5W-WBQAAQBAJ&pg=PT56|url-status=live|archive-url=https://web.archive.org/web/20151124232554/https://books.google.ca/books?id=5W-WBQAAQBAJ&pg=PT56|archive-date=24 November 2015}}</ref> It is on the ].It is on the ].<ref name="WHO23rd">{{cite book | vauthors = ((World Health Organization)) | title = The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) | year = 2023 | hdl = 10665/371090 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2023.02 | hdl-access=free }}</ref> It is derived from ].<ref name=AHFS2016/>
{{TOC limit}}

==Medical uses==
Amikacin is most often used for treating severe infections with ], aerobic ] bacteria, especially '']'', '']'', '']'', '']'', '']'', '']'', and '']''.<ref name="Amikacin sulfate FDA label">{{cite web | title=Amikacin sulfate injection, solution | website=DailyMed | date=10 April 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f57839-1c9b-49e5-8c7a-708e2d16495d | access-date=13 March 2020}}</ref> The only ] bacteria that amikacin strongly affects are '']''<ref name="Amikacin sulfate FDA label" /> and '']''.<ref>{{cite book | vauthors = Scholar EM, Pratt WB | title=The Antimicrobial Drugs | date=22 May 2000 | pages=15–19 | url=https://books.google.com/books?id=gACeB8XCnpgC&pg=PA15 | edition=2nd | publisher=Oxford University Press, USA | isbn=978-0-19-975971-2 | url-status=live | archive-url=https://web.archive.org/web/20170910172330/https://books.google.com/books?id=gACeB8XCnpgC&pg=PA15 | archive-date=10 September 2017 }}</ref> Amikacin can also be used to treat non-tubercular ] infections and tuberculosis (if caused by sensitive strains) when first-line drugs fail to control the infection.<ref name=AHFS2016 /> It is rarely used alone.<ref name=cunha>{{cite journal | vauthors = Cunha BA | title = New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited | journal = The Medical Clinics of North America | volume = 90 | issue = 6 | pages = 1089–1107 | date = November 2006 | pmid = 17116438 | doi = 10.1016/j.mcna.2006.07.006 | series = Antimicrobial Therapy | s2cid = 30373734 }}</ref>

It is often used in the following situations:<ref name=AHFS2016 />
* ]<ref name=medscape>{{cite web | work=Medscape | title=amikacin (Rx) | publisher=WebMD | access-date=9 August 2017 | url=http://reference.medscape.com/drug/amikin-amikacin-342516#0 | url-status=live | archive-url=https://web.archive.org/web/20170809083119/http://reference.medscape.com/drug/amikin-amikacin-342516 | archive-date=9 August 2017 }}</ref>
* Bone and joint infections
* ], when combined with ], in people with cancer<ref name="aronson">{{cite book |editor=Aronson J. K.| title=Meyler's Side Effects of Drugs | chapter=Amikacin | location=Oxford | date=2016 | edition=16th | publisher=Elsevier | isbn=978-0-444-53716-4 | pages=207–209}}</ref>
* Intra-abdominal infections (such as ]) as an adjunct to other medicines, like ], ], ]/], or ]/]
* ]:
** for meningitis by ''E. coli'', as an adjunct to ]
** for meningitis caused by ''Pseudomonas'', as an adjunct to ]
** for meningitis caused by ''Acinetobacter'', as an adjunct to imipenem or ]
** for ] caused by '']'' or '']'', as an adjunct to ampicillin
** for neonatal meningitis caused by Gram negative bacteria such as ''E. coli'', as adjunct to a ]
* Mycobacterial infections, including as a second-line agent for active ].<ref>{{cite book | vauthors = Vardanyan R, Hruby V | title=Synthesis of Best-Seller Drugs | chapter=Chapter 32: Antimicobacterial Drugs | location=Boston| date=2016| publisher=Academic Press | isbn=978-0-12-411492-0 | pages=669–675}}</ref> It is also used for infections by '']'', '']'', '']'', and '']''.
* '']'', which causes an infection resembling tuberculosis
* Respiratory tract infections, including as an adjunct to ]s or ] for ]
* ], including that in neonates,<ref name="Amikacin sulfate FDA label" /> as an adjunct to beta-lactams or carbapenem
* Skin and suture-site infections<ref name="Amikacin sulfate FDA label" />
* ]s that are caused by bacteria resistant to less toxic drugs (often by '']'' or ''P. aeruginosa)''

Amikacin may be combined with a beta-lactam antibiotic for ] for people with ] and ].<ref name=AHFS2016 />

===Available forms===
A liposome inhalation suspension is also available and approved to treat ] (MAC) in the United States,<ref name="FDA PR">{{cite press release |title=FDA approves a new antibacterial drug to treat a serious lung disease using a novel pathway to spur innovation |url=https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibacterial-drug-treat-serious-lung-disease-using-novel-pathway-spur-innovation |website=U.S. ] (FDA) |access-date=12 November 2018 }} {{PD-notice}}</ref><ref name="Arikayce FDA label">{{cite web | title=Arikayce- amikacin suspension | website=DailyMed | date=30 September 2018 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=499ab990-2b21-474f-aaba-d86388965f40 | access-date=13 March 2020}}</ref> and in the European Union.<ref name="Arikayce liposomal EPAR" />

Amikacin liposome inhalation suspension is the first drug approved under the US ] (LPAD pathway).<ref name="FDA PR" /> It also was approved under the ] pathway.<ref name="FDA PR" /> The US ] (FDA) granted the application for amikacin liposome inhalation suspension ], ], ], and ] (QIDP) designations.<ref name="FDA PR" /> The FDA granted approval of Arikayce to Insmed, Inc.<ref name="FDA PR" />

The safety and efficacy of amikacin liposome inhalation suspension, an inhaled treatment taken through a nebulizer, was demonstrated in a randomized, controlled clinical trial where patients were assigned to one of two treatment groups.<ref name="FDA PR" /> One group of patients received amikacin liposome inhalation suspension plus a background multi-drug antibacterial regimen, while the other treatment group received a background multi-drug antibacterial regimen alone.<ref name="FDA PR" /> By the sixth month of treatment, 29 percent of patients treated with amikacin liposome inhalation suspension had no growth of mycobacteria in their sputum cultures for three consecutive months compared to 9 percent of patients who were not treated with amikacin liposome inhalation suspension.<ref name="FDA PR" />

===Special populations===
Amikacin should be used in smaller doses in the elderly, who often have age-related decreases in kidney function, and children, whose kidneys are not fully developed yet. It is considered ] D in both the United States and Australia, meaning they have a probability of harming the fetus.<ref name=AHFS2016/> Around 16% of amikacin crosses the placenta; while the half-life of amikacin in the mother is 2 hours, it is 3.7 hours in the fetus.<ref name="Amikacin sulfate FDA label" /> A pregnant woman taking amikacin with another aminoglycoside has a possibility of causing ] in her child. While it is known to cross the placenta, amikacin is only partially secreted in breast milk.<ref name=AHFS2016/>

In general, amikacin should be avoided in infants.<ref name=ettinger>{{cite book | vauthors = Ettinger SJ, Feldman EC | title=Textbook of Veterinary Internal Medicine | date=24 December 2009 | pages=1976, 523 | url=https://books.google.com/books?id=4Qzau1jagOYC&pg=PA1976 | publisher=Elsevier Health Sciences | isbn=978-1-4377-0282-8 | url-status=live | archive-url=https://web.archive.org/web/20170910172330/https://books.google.com/books?id=4Qzau1jagOYC&pg=PA1976 | archive-date=10 September 2017 }}</ref> Infants also tend to have a larger volume of distribution due to their higher concentration of ], where aminoglycosides reside.<ref name=plumb />

The elderly tend to have amikacin stay longer in their system; while the average clearance of amikacin in a 20-year-old is 6 L/hr, it is 3 L/hr in an 80-year-old.<ref name=maire>{{cite book | vauthors = Maire P, Bourguignon L, Goutelle S, Ducher M, Jelliffe R | chapter=Chapter 20 – Individualizing Drug Therapy in the Elderly | veditors = Jelliffe RW, Neely M | title=Individualized Drug Therapy for Patients | location=Boston | date=2017 | publisher=Academic Press | isbn=978-0-12-803348-7 | pages=373–382}}</ref>

Clearance is even higher in people with cystic fibrosis.<ref name="eghianruwa">{{cite book | vauthors = Eghianruwa K | title=Essential Drug Data for Rational Therapy in Veterinary Practice | date=2014 | page=16 | url=https://books.google.com/books?id=h4zCAgAAQBAJ&pg=PA16 | publisher=Author House | isbn=978-1-4918-0000-3 | url-status=live | archive-url=https://web.archive.org/web/20170910172330/https://books.google.com/books?id=h4zCAgAAQBAJ&pg=PA16 | archive-date=10 September 2017 }}</ref>

In people with muscular disorders such as ] or ], amikacin's paralytic effect on neuromuscular junctions can worsen muscle weakness.<ref name=AHFS2016/>

==Adverse effects==
Side-effects of amikacin are similar to those of other aminoglycosides. ] and ] (which can lead to hearing loss) are the most important effects, occurring in 1–10% of users.<ref name=medscape /> The nephro- and ototoxicity are thought to be due to aminoglycosides' tendency to accumulate in the kidneys and inner ear.<ref name=plumb />

]

Amikacin can cause neurotoxicity if used at a higher dose or for longer than recommended. The resulting effects of neurotoxicity include ], ], ] of the skin (]), muscle ], and ].<ref name=AHFS2016 /> Its toxic effect on the 8th ] causes ototoxicity, resulting in loss of balance and, more commonly, hearing loss.<ref name="plumb" >{{cite book | vauthors = Plumb DC | title=Plumb's Veterinary Drug Handbook | chapter=Amikacin Sulfate | location=Stockholm, Wisconsin; Ames, Iowa | date=2011 | edition=7th | publisher=Wiley | isbn=978-0-470-95964-0 | pages=39–43}}</ref> Damage to the ], caused by the forced ] of the ]s, leads to the loss of high-frequency hearing and happens before any clinical hearing loss can be detected.<ref name="Amikacin sulfate FDA label" /><ref name="morris">{{cite book | vauthors = Morris DO, Kennis RA | title=Clinical Dermatology, An Issue of Veterinary Clinics: Small Animal Practice, E-Book | date=11 October 2012 | page=29 | url=https://books.google.com/books?id=TsKQVAWxHg4C&pg=PA29 | publisher=Elsevier Health Sciences | isbn=978-1-4557-7377-0 | url-status=live | archive-url=https://web.archive.org/web/20170910172330/https://books.google.com/books?id=TsKQVAWxHg4C&pg=PA29 | archive-date=10 September 2017 }}</ref> Damage to the ], most likely by creating excessive oxidative ]. It does so in a time-dependent rather than dose-dependent manner, meaning that risk can be minimized by reducing the duration of use.<ref name="corti">{{cite journal | vauthors = Corti N, Taegtmeyer A, Imhof A | title=Miscellaneous antibacterial drugs | journal=Side Effects of Drugs Annual | series=A worldwide yearly survey of new data in adverse drug reactions | date=1 January 2011 | doi=10.1016/B978-0-444-53741-6.00026-X | issn=0378-6080 | volume=33 | pages=509–540| isbn=9780444537416 }}</ref>

Amikacin causes nephrotoxicity (damage to the kidneys), by acting on the ]s. It easily ionizes to a ] and binds to the ] sites of the epithelial cells of the proximal tubule as part of receptor-mediated ]. The concentration of amikacin in the ] becomes ten times that of amikacin in the plasma;<ref name="ettinger" /> it then most likely interferes with the metabolism of ] in the ], which causes lytic enzymes to leak into the cytoplasm.<ref name="plumb" /> Nephrotoxicity results in increased serum ], ], ], and ], as well as ] (increased output of ] in the urine), ] (excretion of glucose into the urine), decreased urine ], and ] (decrease in overall urine output).<ref name="Amikacin sulfate FDA label" /><ref name="morris" /> It can also cause ] to appear.<ref name="plumb" /> The changes in ] function also change the electrolyte levels and acid-base balance in the body, which can lead to ] and ] or ].<ref name="corti" /> Nephrotoxicity is more common in those with pre-existing hypokalemia, ], ], acidosis, low ], ] mellitus, dehydration, fever, and ], as well as those taking ].<ref name=AHFS2016 /><ref name="ettinger" /><ref name="plumb" /><ref name="corti" /> The toxicity usually reverts once the antibiotic course has been completed,<ref name="plumb" /> and can be avoided altogether by less frequent dosing (such as once every 24 hours rather than once every 8 hours).<ref name="ettinger" />

Amikacin can cause neuromuscular blockade (including acute muscular paralysis) and respiratory paralysis (including ]).<ref name=AHFS2016 />

Rare side effects (occurring in fewer than 1% of users) include allergic reactions, ], ], ]s, ], ] and ], ], ], ], ], and hypomagnesemia. In intravitreous injections (where amikacin is injected into the eye), macular ] can cause permanent vision loss.<ref name="Amikacin sulfate FDA label" /><ref name=medscape />

The amikacin liposome inhalation suspension prescribing information includes a boxed warning regarding the increased risk of respiratory conditions including hypersensitivity pneumonitis (inflamed lungs), bronchospasm (tightening of the airway), exacerbation of underlying lung disease and hemoptysis (spitting up blood) that have led to hospitalizations in some cases.<ref name="FDA PR" /><ref name="Arikayce FDA label" /> Other common side effects in patients taking amikacin liposome inhalation suspension are dysphonia (difficulty speaking), cough, ototoxicity (damaged hearing), upper airway irritation, musculoskeletal pain, fatigue, diarrhea and nausea.<ref name="FDA PR" /><ref name="Arikayce FDA label" />

==Contraindications==
Amikacin should be avoided in those who are sensitive to ''any'' aminoglycoside, as they are cross-allergenic (that is, an allergy to one aminoglycoside also confers hypersensitivity to other aminoglycosides). It should also be avoided in those sensitive to ] (seen more among people with asthma),<ref name="Amikacin sulfate FDA label" /> since most amikacin usually comes with ], which can cause an allergic reaction.<ref name=AHFS2016 />

In general, amikacin should not be used with or just before/after another drug that can cause neurotoxicity, ototoxicity, or nephrotoxicity. Such drugs include other aminoglycosides; the antiviral ]; the antifungal ]; the antibiotics ], ], colistin, ], and ]; and ], which is used in ].<ref name=AHFS2016 />

Amikacin should not be used with ], as they can increase muscle weakness and paralysis.<ref name=AHFS2016 />

== Interactions ==

Amikacin can be inactivated by other beta-lactams, though not to the extent as other aminoglycosides, and is still often used with ] (a type of beta-lactam) to create an additive effect against certain bacteria, and carbapenems, which can have a synergistic effect against some Gram-positive bacteria. Another group of beta-lactams, the cephalosporins, can increase the nephrotoxicity of aminoglycoside as well as randomly elevating ] levels. The antibiotics ], clindamycin, and ] have been known to inactivate aminoglycosides in general by pharmacological antagonism.<ref name=AHFS2016 />

The effect of amikacin is increased when used with drugs derived from the ],<ref name=medscape /> ]s, neuromuscular blocking agents, or large doses of blood that contains ] as an ].<ref name=AHFS2016 />

Potent diuretics not only cause ototoxicity themselves, but they can also increase the concentration of amikacin in the serum and tissue, making the ototoxicity even more likely.<ref name=AHFS2016 /> ] also increases levels of amikacin in the body.<ref name=medscape /> The ] ] can increase serum aminoglycoside levels in premature infants.<ref name=AHFS2016 /> Contrast mediums such as ] increases the nephrotoxicity and otoxicity caused by amikacin.<ref name=medscape />

Amikacin can decrease the effect certain vaccines, such as the live ] (used for tuberculosis), the ], and the live ] by acting as a pharmacological antagonist.<ref name=medscape />

==Pharmacology==
===Mechanism of action===
]

Amikacin irreversibly binds to ] and the RNA-binding ] of the ] subunit of prokaryotic ] and inhibits protein synthesis by changing the ribosome's shape so that it cannot read the ] ]s correctly.<ref name="Amikacin sulfate FDA label" /><ref name="bauman">{{cite book | vauthors = Bauman RW | title=Microbiology: with diseases by body system | location=Boston | date=2015 | edition=4th | publisher=Pearson | isbn=978-0-321-91855-0}}</ref> It also interferes with the region that interacts with the ] of the ] anticodon.<ref name="drugbank">{{cite web|url=https://www.drugbank.ca/drugs/DB00479|title=Amikacin|date=2 August 2017|work=DrugBank|access-date=10 August 2017|url-status=live|archive-url=https://web.archive.org/web/20170816150102/https://www.drugbank.ca/drugs/DB00479|archive-date=16 August 2017}}</ref> It works in a concentration-dependent manner, and has better action in an alkaline environment.<ref name="plumb" />

At normal doses, amikacin-sensitive bacteria respond within 24–48 hours.<ref name="Amikacin sulfate FDA label" />

====Resistance====
Amikacin evades attacks by all antibiotic-inactivating enzymes that are responsible for ] in bacteria, except for aminoacetyltransferase and ].<ref name=mudd>{{cite web | vauthors = Mudd E | title=O Aminoglycosides | work=Pharmacological Sciences | access-date=14 August 2017 | date=7 August 2017 | url=https://www.pharmacologicalsciences.us/pharmaceutical-chemistry/o-aminoglycosides.html | url-status=live | archive-url=https://web.archive.org/web/20170816105922/https://www.pharmacologicalsciences.us/pharmaceutical-chemistry/o-aminoglycosides.html | archive-date=16 August 2017 }}</ref> This is accomplished by the <small>L</small>-hydroxyaminobuteroyl amide (L-HABA) moiety attached to N-1 (compare to ], which simply has a hydrogen), which blocks the access and decreases the affinity of aminoglycoside-inactivating enzymes.<ref name=mudd /><ref name=kondo>{{cite journal | vauthors = Kondo S, Hotta K | title = Semisynthetic aminoglycoside antibiotics: Development and enzymatic modifications | journal = Journal of Infection and Chemotherapy | volume = 5 | issue = 1 | pages = 1–9 | date = March 1999 | pmid = 11810483 | doi = 10.1007/s101560050001 | s2cid = 38981498 }}</ref><ref name=park>{{cite journal | vauthors = Park JW, Ban YH, Nam SJ, Cha SS, Yoon YJ | title = Biosynthetic pathways of aminoglycosides and their engineering | journal = Current Opinion in Biotechnology | volume = 48 | pages = 33–41 | date = December 2017 | pmid = 28365471 | doi = 10.1016/j.copbio.2017.03.019 | series = Chemical biotechnology: Pharmaceutical biotechnology }}</ref> Amikacin ends up with only one site where these enzymes can attack, while gentamicin and tobramycin have six.<ref name=cunha />

Bacteria that are resistant to ] and capreomycin are still susceptible to amikacin; bacteria that are resistant to kanamycin have varying susceptibility to amikacin. Resistance to amikacin also confers resistance to kanamycin and capreomycin.<ref name=caminero>{{cite journal | vauthors = Caminero JA, Sotgiu G, Zumla A, Migliori GB | title = Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis | journal = The Lancet. Infectious Diseases | volume = 10 | issue = 9 | pages = 621–629 | date = September 2010 | pmid = 20797644 | doi = 10.1016/S1473-3099(10)70139-0 }}</ref>

Resistance to amikacin and kanamycin in ''Mycobacterium'', the causative agent of tuberculosis, is due to a mutation in the ''rrs'' gene, which codes for the 16S rRNA. Mutations such as these reduce the binding affinity of amikacin to the bacteria's ribosome.<ref name="ahmad">{{cite journal | vauthors = Ahmad S, Mokaddas E | title = Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis | journal = Journal of Infection and Public Health | volume = 7 | issue = 2 | pages = 75–91 | date = 1 March 2014 | pmid = 24216518 | doi = 10.1016/j.jiph.2013.09.001 | doi-access = }}</ref> Variations of aminoglycoside ] (AAC) and aminoglycoside ] (AAD) also confer resistance: resistance in ''Pseudomonas aeruginosa'' is caused by AAC(6')-IV, which also confers resistance to kanamycin, gentamicin, and tobramycin, and resistance in '']'' and '']'' is caused by AAD(4',4''), ''which also confers resistance to kanamycin, tobramycin, and apramycin.<ref name="kondo" /> Some strains of ''S. aureus'' can also inactivate amikacin by phosphorylating it.<ref name="aronson" />

===Pharmacokinetics===
Amikacin is not absorbed orally and thus must be administered parenterally. It reaches peak serum concentrations in 0.5–2 hours when administered intramuscularly. Less than 11% of the amikacin actually binds to plasma proteins. It is distributed into the ], ], ], and ]s, as well as in ], ], ], ], and ]. It is usually found at low concentrations in the ], except when administered intraventricularly.<ref name=AHFS2016 /> In infants, amikacin is normally found at 10–20% of plasma levels in the spinal fluid, but the amount reaches 50% in cases of meningitis.<ref name="Amikacin sulfate FDA label" /> It does not easily cross the ] or enter ocular tissue.<ref name=plumb />

While the half-life of amikacin is normally two hours, it is 50 hours in those with end-stage renal disease.<ref name=cunha />

The majority (95%) of amikacin from an intramuscular or intravenous dose is secreted unchanged via ] and into the urine within 24 hours.<ref name=AHFS2016 /><ref name=cunha /> Factors that cause amikacin to be excreted via urine include its relatively low molecular weight, high water solubility, and unmetabolized state.<ref name=ettinger />

==Chemistry==
Amikacin is derived from ]:<ref name=kawaguchi>{{cite journal | vauthors = Kawaguchi H, Naito T, Nakagawa S, Fujisawa KI | title = BB-K 8, a new semisynthetic aminoglycoside antibiotic | journal = The Journal of Antibiotics | volume = 25 | issue = 12 | pages = 695–708 | date = December 1972 | pmid = 4568692 | doi = 10.7164/antibiotics.25.695 | url = https://www.jstage.jst.go.jp/article/antibiotics1968/25/12/25_12_695/_pdf | url-status = live | doi-access = free | archive-url = https://web.archive.org/web/20170816105728/https://www.jstage.jst.go.jp/article/antibiotics1968/25/12/25_12_695/_pdf | archive-date = 16 August 2017 }}</ref><ref name=monteleone>{{cite book | vauthors = Monteleone PM, Muhammad N, Brown RD, McGrory JP, Hanna SA | title=Amikacin Sulfate | date=1 January 1983| doi=10.1016/S0099-5428(08)60163-X | issn=0099-5428 | volume=12 | pages=37–71| series=Analytical Profiles of Drug Substances | publisher=Academic Press | isbn=9780122608124 }}</ref>

]

==Veterinary uses==
While amikacin is only FDA-approved for use in dogs and for intrauterine infection in horses, it is one of the most common aminoglycosides used in veterinary medicine,<ref name=forney>{{cite web | vauthors = Forney B | title=Amikacin for Veterinary Use | work=Wedgewood Pharmacy | access-date=9 August 2017 | url=http://www.wedgewoodpetrx.com/learning-center/professional-monographs/amikacin-for-veterinary-use.html | url-status=live | archive-url=https://web.archive.org/web/20170816110344/http://www.wedgewoodpetrx.com/learning-center/professional-monographs/amikacin-for-veterinary-use.html | archive-date=16 August 2017 }}</ref> and has been used in dogs, cats, ]s, ]s, ]s, ]s, ], ]s, ], ]s, ]s, ]s and ]s, ]ns, ], and ]<!--no, really-->.<ref name=plumb /><ref>{{cite book | vauthors = Riviere JE, Papich MG | title=Veterinary Pharmacology and Therapeutics | date=13 May 2013 | page=931 | url=https://books.google.com/books?id=xAPa4WDzAnQC&pg=PA931 | publisher=John Wiley & Sons | isbn=978-1-118-68590-7 | url-status=live | archive-url=https://web.archive.org/web/20170910172330/https://books.google.com/books?id=xAPa4WDzAnQC&pg=PA931 | archive-date=10 September 2017 }}</ref><ref>{{cite book | vauthors = Mader DR, Divers SJ | title=Current Therapy in Reptile Medicine and Surgery – E-Book | date=12 December 2013 | page=382 | url=https://books.google.com/books?id=2phWAgAAQBAJ&pg=PA382 | publisher=Elsevier Health Sciences | isbn=978-0-323-24293-6 | url-status=live | archive-url=https://web.archive.org/web/20170910172330/https://books.google.com/books?id=2phWAgAAQBAJ&pg=PA382 | archive-date=10 September 2017 }}</ref> It is often used for respiratory infections in snakes, bacterial shell disease in turtles, and ] in ]s. It is generally contraindicated in ]s and ]s (though it has still been used) because it harms the balance of ].<ref name=plumb />

In dogs and cats, amikacin is commonly used as a topical antibiotic for ] and for ], especially those that are caused by ''Pseudomonas aeruginosa''. The ears are often cleaned before administering the medication, since ] and cellular debris lessen the activity of amikacin.<ref name=forney /> Amikacin is administered to the eye when prepared as an ophthalmic ointment or solution, or when injected ].<ref>{{cite book | vauthors = Maggs D, Miller P, Ofri R | title=Slatter's Fundamentals of Veterinary Ophthalmology – E-Book | date=7 August 2013 | page=37 | url=https://books.google.com/books?id=8QCduRN3zR0C&pg=PA37 | publisher=Elsevier Health Sciences | isbn=978-0-323-24196-0 | url-status=live | archive-url=https://web.archive.org/web/20170910172330/https://books.google.com/books?id=8QCduRN3zR0C&pg=PA37 | archive-date=10 September 2017 }}</ref> Amikacin in the eye can be accompanied by ]. Despite its use there amikacin (and all aminoglycosides) are toxic to intraocular structures.<ref>{{cite book | vauthors = Hsu WH | title=Handbook of Veterinary Pharmacology | date=25 April 2013 | publisher=John Wiley & Sons | isbn=978-1-118-71416-4 | url=https://books.google.com/books?id=MGhScg9GZGAC&pg=PT486 | page=486}}</ref>

In horses, amikacin is FDA-approved for uterine infections (such as ] and ]) when caused by susceptible bacteria.<ref name="Amiglyde-V FDA label">{{cite web | publisher = U.S. National Library of Medicine | title=Amiglyde-V- amikacin sulfate injection | work=DailyMed | access-date=8 August 2017 | date=9 March 2017 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2abecaf-9532-45a0-a284-5697b2aa38f1 | url-status=live | archive-url=https://web.archive.org/web/20170816110928/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2abecaf-9532-45a0-a284-5697b2aa38f1 | archive-date=16 August 2017 }}</ref> It is also used in topical medication for the eyes and ]; when combined with a cephalosporin, is used to treat ] infections that are caused by ''Staphylococcus''. For infections in the limbs or joints, it is often administered with a cephalosporin via ] directly into the limb or ].<ref name=forney /><ref name=orsini>{{cite journal | vauthors = Orsini JA | title=Update on Managing Serious Wound Infections in Horses: Wounds Involving Joints and Other Synovial Structures | journal=Journal of Equine Veterinary Science | date=1 August 2017| doi=10.1016/j.jevs.2017.01.016 | issn=0737-0806 | volume=55 | pages=115–122}}</ref> Amikacin is also injected into the joints with the anti-arthritic medication ] in order to prevent infection.<ref>{{cite book | vauthors = Wanamaker BP, Massey K | title=Applied Pharmacology for Veterinary Technicians – E-Book | date=25 March 2014 | page=392 | publisher=Elsevier Health Sciences | isbn=978-0-323-29170-5}}</ref>

Side effects in animals include nephrotoxicity, ototoxicity, and ]. Cats tend to be more sensitive to the vestibular damage caused by ototoxicity. Less frequent side effects include neuromuscular blockade, facial ], and ].<ref name="plumb" /><ref name=forney />

The half-life in most animals is one to two hours.<ref name=papich>{{cite book | vauthors = Papich MG | title=Saunders Handbook of Veterinary Drugs: Small and Large Animal | chapter=Amikacin | date=October 2015 | chapter-url=https://books.google.com/books?id=ip8_CwAAQBAJ&pg=PA25 | edition=4th | publisher=Elsevier Health Sciences | isbn=978-0-323-24485-5 | pages=25–27 | url-status=live | archive-url=https://web.archive.org/web/20170910172330/https://books.google.com/books?id=ip8_CwAAQBAJ&pg=PA25 | archive-date=10 September 2017 }}</ref>

Treating overdoses of amikacin requires ] or ], which reduce serum concentrations of amikacin, and/or penicillins, some of which can form complexes with amikacin that deactivate it.<ref name=plumb />

== References ==
{{reflist}}

{{Antibiotics and chemotherapeutics for dermatological use}}
{{AminoglycosideAntiBiotics}}
{{Portal bar | Medicine}}
{{Authority control}}

]
]
]
]
]
]